P0848 - Mirikizumab Effect on Bowel Urgency Resolution in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

Vipul Jairath, MBChB¹, Bruce E.. Sands, MD, FACG², Maria Chaparro, MD, PhD³, Minhu Chen, ⁴, Geert R. D'Haens, MD, PhD⁵, Marla C. Dubinsky, MD², Marc Ferrante, MD, PhD⁶, Laurent Peyrin-Biroulet, MD, PhD⁷, Stefan Schreiber, MD⁸, Simon Travis, ⁹, Hilde Carlier, ¹⁰, Zhantao Lin, PhD¹⁰, Richard Moses, ¹⁰, Marijana Protic, ¹⁰, Aisha Vadhariya, ¹⁰, Konstantinos Tsilkos, ¹⁰, Subrata Ghosh, MD^11
1Western University, London, ON, Canada; ²Icahn School of Medicine at Mount Sinai, New York, NY; ³Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigacíon Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Diego de León, Madrid, Spain; ⁴First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; ⁵Amsterdam University Medical Center, Amsterdam, Limburg, Netherlands; ⁶University Hospitals, Leuven, Vlaams-Brabant, Belgium; ⁷INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France; McGill University Health Centre, Montreal, QC, Canada, Nancy, Lorraine, France; ⁸University Hospital, Kiel, Schleswig-Holstein, Germany; ⁹University of Oxford, Oxford, England, United Kingdom; ¹⁰Eli Lilly and Company, Indianapolis, IN; ¹¹University College Cork, Cork, Cork, Ireland

Introduction: Bowel urgency (BU), the sudden or immediate need to have a bowel movement, is an impactful symptom of Crohn’s disease (CD) that varies in intensity. We report the efficacy of the IL-23 p19 inhibitor, mirikizumab (miri) in improving BU among patients with moderately-to-severely active CD from the phase 3 VIVID-1 trial (NCT03926130). VIVID-1 co-primary and gated endpoints, including comparison with ustekinumab, are already reported.

Methods: Adult patients (N=1065) were randomised to placebo (PBO) or miri 900mg intravenously at weeks (W) 0, 4, and 8, then 300mg subcutaneously every 4 weeks (Q4W) from W12 to W52. At W12, PBO responders continued PBO to W52, non-responders received the blinded miri regimen per protocol. BU was assessed at W12 and W52 using the Urgency Numeric Rating Scale (UNRS). We evaluated the proportion of patients with baseline (BL) UNRS ≥3 and ≥6 who achieved BU Clinically Meaningful Improvement (CMI; >3 change in UNRS) and BU remission (UNRS ≤2). Treatment comparisons used Cochran-Mantel-Haenszel tests with non-responder imputation for missing values.

Results: Study population: 55.1% male. Mean (SD) age 36.2 (13.0) years. Disease duration 7.4 (7.9) years. At BL, median (Q1, Q3) UNRS 6.9 (5.2, 8.1), 94.5% patients achieved UNRS ≥3 and 66.0% patients achieved ≥6. In patients with BL UNRS ≥3, nominally significantly higher proportions of miri versus PBO patients achieved BU CMI and BU remission at both W12 and W52 (Table). A nominally significantly greater proportion of miri-treated patients achieved W52 BU CMI-composite and BU remission-composite (Table). Similar results were seen with BL UNRS ≥6.

Discussion: BU is one of the most unrecognised symptoms in patients with CD. Patients enrolled in VIVID-1 had high BU scores at BL. Compared to PBO-treated patients, miri-treated patients achieved nominally significantly higher rates of BU CMI and remission at W12 and W52.


Disclosures:


Vipul Jairath, MBChB¹, Bruce E.. Sands, MD, FACG², Maria Chaparro, MD, PhD³, Minhu Chen, ⁴, Geert R. D'Haens, MD, PhD⁵, Marla C. Dubinsky, MD², Marc Ferrante, MD, PhD⁶, Laurent Peyrin-Biroulet, MD, PhD⁷, Stefan Schreiber, MD⁸, Simon Travis, ⁹, Hilde Carlier, ¹⁰, Zhantao Lin, PhD¹⁰, Richard Moses, ¹⁰, Marijana Protic, ¹⁰, Aisha Vadhariya, ¹⁰, Konstantinos Tsilkos, ¹⁰, Subrata Ghosh, MD¹¹. P0848 - Mirikizumab Effect on Bowel Urgency Resolution in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.